Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
A new study from Massachusetts General Hospital finds that cigarette smoking significantly reduces the lifespan of people living with HIV in the U.S., potentially even more than HIV itself. Quitting smoking can greatly increase lifespan and is never too late to quit.
Researchers at Georgetown University Medical Center have developed a method to study cancer cell invasion and metastasis in real-time using zebrafish embryos. This approach allows for faster analysis of cancer questions, potentially leading to new treatments.
The SWOG and The Hope Foundation's efforts are paying off, with 13 NCTN trials now open to veterans at participating medical centers. Veterans like Jerry Valentino have successfully enrolled in trials, responding well to cutting-edge treatments.
A study published in The New England Journal of Medicine details two cases of acute and unexpected fatal myocarditis that occurred in melanoma patients following treatment with a combination of ipilimumab and nivolumab. High-dose corticosteroids were initially administered, but both patients died due to the severe immune reaction.
Researchers at The Wistar Institute have developed a combination therapy that improves chemoresistance in ovarian cancer. BET inhibitors can suppress ALDH activity, making treatment more effective when used with cisplatin. This approach has shown extended survival rates and delayed tumor growth in mice.
Researchers found that high levels of Manganese Superoxide Dismutase (MnSOD) trigger aggressive breast cancer cell behavior. By targeting MnSOD, scientists hope to develop effective therapeutic strategies against triple-negative breast cancer.
A new study identifies the Hedgehog signaling pathway as a central driver of gastrointestinal stromal tumors (GIST), which are often resistant to current treatments. Researchers have found that targeting this pathway with arsenic may offer a new approach to treatment, potentially killing multidrug-resistant cell lines.
A recent study found that hybrid structures composed of DNA and RNA play a crucial role in restoring genetic information after damage. The research also revealed that RNase H enzymes targeting these hybrids are vital for efficient DNA repair. This discovery offers potential for developing new cancer drugs targeting these enzymes.
The article explores the economic aspects of cancer care, highlighting the need to assess the value of healthcare innovation. It discusses the rising costs of new treatments and the potential impact on healthcare budgets. The Special Issue provides a review of health economics in cancer research and care.
Researchers at Boston University School of Medicine have discovered a potential treatment option for ovarian cancer by combining calpeptin with epigenetic inhibitors. The therapy shows promise in killing cancer cells and preventing their growth, offering new hope for women affected by the disease.
A new Penn Medicine study fails to find NLR reliable for predicting cancer progression and treatment response in bladder cancer patients. The researchers analyzed data from a prospective clinical trial, which showed that NLR was not effective as a prognostic or predictive biomarker.
Researchers developed a way to attach labels to cancer drugs packaged in liposomes, allowing for imaging with PET to see where they accumulate in the body. This method shows promise in predicting drug delivery to cancer tissues in specific patients, potentially leading to more effective treatments and reduced side effects.
A recent study published in JAMA Internal Medicine estimates that nearly 40% of cancer deaths in men are linked to smoking, with the South experiencing the highest rates. The research suggests that weaker tobacco control policies and lower socioeconomic status contribute to these disparities.
Researchers at Aarhus University combined two scanning technologies to create high-resolution images of cancer tumors in mice, providing detailed mapping of blood vessels. This method could lead to the development of more effective drugs and personalized treatment plans.
Researchers use fission yeast to discover new cancer drugs targeting active proteins involved in DNA replication. The unique "arched and snapped" appearance of treated cells suggests potential for accelerating drug development.
Researchers at MUSC Hollings Cancer Center discover a mechanism conferring resistance to AML drugs and develop a ceramide-based therapeutic that reactivates mitophagy, killing drug-resistant cancer cells. The treatment has clinical appeal due to its specificity towards cancer cells.
Scientists at TUM have discovered new mechanisms of action for Imiquimod, a medication used to treat viral skin infections and certain types of skin cancer. The study reveals that Imiquimod activates the NLRP3 inflammasome, which can lead to inflammation and potentially contribute to its efficacy or adverse side effects.
A new compound, S63845, has been shown to block a protein essential for the sustained growth of up to a quarter of all cancers. This research holds promise for treating blood and solid cancers, including acute myeloid leukaemia and melanoma.
Researchers at Johns Hopkins Medicine have developed a modified cancer drug that enhances its ability to reach the brain, improving delivery and reducing toxicity. The new compound shows promise in treating brain tumors by targeting tumor metabolism and evading immune cells.
Rural Appalachia faces alarming disparities in cancer care, including higher mortality rates, late diagnoses, and limited access to comprehensive treatment. The region has seen a decline in cancer incidence nationwide, but its cancer death rate has increased, with rural residents facing significantly worse outcomes.
Researchers at USC Fertility found modified natural cycle IVF to be a cost-effective fertility method, saving up to $7,000 per live birth compared to conventional IVF. This approach takes less time and is gentler on the body, making it more accessible to younger patients.
Eleven cancers causing most loss of healthy life years in the US are closely associated with preventable risk factors like smoking and alcohol. Lung cancer accounts for 24% of the burden, followed by breast, colorectal, pancreatic, prostate, leukemia, liver, brain, non-Hodgkin lymphoma, and ovarian cancers.
Researchers develop artificial cell-like spheres from natural proteins to study drug transport and variability. Variants in genes ABCB1 and CYP19A1 associated with anastrozole concentrations and joint pain in breast cancer patients.
Researchers at Weill Cornell Medicine found that chemotherapy kills urothelial cancer cells but shapes their genetic evolution, leading to drug-resistant cell clones. This study provides a framework for understanding the biological basis of chemotherapy resistance in bladder cancer and may lead to improved diagnostics and treatments.
Researchers at Hokkaido University discovered that a nonsteroid anti-inflammatory drug used for treating colds can suppress the spread of bladder cancers and reduce chemoresistance in mice. The study identified the metabolic enzyme aldo-keto reductase 1C1 (AKR1C1) as a key player in cancer progression.
A recent scandal in Brazil highlights the dangers of unproven compounds being sold to cancer patients. The authors argue that skipping clinical research phases puts patients at risk of false hopes and dangerous treatments. They emphasize the need for evidence-based medicine and the importance of testing novel drug candidates.
Researchers from the Repurposing Drugs in Oncology project found that propranolol has significant anti-cancer properties, particularly in angiosarcoma. The study highlights the potential of propranolol to act on multiple points of the metastatic cascade, reducing metastatic spread and saving lives.
Changes in protein modifications generate biological diversity needed for evolution, allowing species to adapt to environments. Most phosphorylation sites arose relatively recently in evolution, contributing significantly to evolutionary diversity and highlighting potential avenues for therapeutic research.
A team of researchers at the Salk Institute has found a way to obstruct the creation of fat molecules in cancer cells, stalling their growth. This approach involves inhibiting an enzyme called Acetyl-CoA Carboxylase, which is crucial for lipid synthesis activity.
Researchers aim to learn about physical parameters limiting drug delivery into brain tumors to improve treatment selection for unique tumors.
A team of international scientists has outlined 14 recommendations to improve the adoption of new cancer scans in clinics. The guidelines aim to address challenges such as variability in methodologies and lack of reproducibility across laboratories.
Scientists at Harvard's Wyss Institute have developed a way to analyze the effect of mechanical stiffness on chemotherapy treatment. The new method uses alginate hydrogels to mimic tumor and normal tissue environments, revealing that softer matrix conditions lead to increased resistance.
A new study suggests that combining an experimental PARP inhibitor with an epigenetic drug can strengthen treatment effectiveness against breast cancer cells without BRCA mutations, as well as leukemia cells. The combination therapy resulted in a strong antitumor response and halted tumor growth.
Researchers discovered a novel mechanism in a combination drug therapy that disrupts cancer cells' ability to survive DNA damage. The therapy combines DNA methyltransferase inhibitors with poly-ADP-ribose polymerase inhibitors, causing massive DNA damage that leads to cancer cell death.
Researchers at MIT and Dana-Farber Cancer Institute developed a novel way to test tumors for drug susceptibility using a device that measures single-cell masses. They successfully tested this approach with glioblastoma and acute lymphocytic leukemia, finding that susceptible cells reduce growth rates while resistant cells continue unaf...
Single-arm trials can provide valuable opportunities for speeding up cancer drug development and approval, particularly in small populations with high unmet medical need. Regulatory guidance is being developed to define evidence requirements for SATs, and initial approvals based on SATs have similar success rates to RCTs.
A genetic signature related to metabolism has been identified as a predictor of poor patient prognosis in cancer. The discovery could lead to the development of targeted treatments and personalized therapy approaches. Further validation is needed to confirm the link between mitochondrial function and cancer survival.
A survey by Dr Lidija Kandolf-Sekulovic found that over 5000 European melanoma patients are denied access to innovative treatments each year. In Eastern Europe, only 42% of countries have registered the treatment, and only 18% have full reimbursement coverage.
A survey found that over 5,000 metastatic melanoma patients in Europe are denied access to innovative treatments annually. The inequality affects Eastern and South-Eastern European countries more severely, where only 10% of patients have access to the latest treatment recommended by current guidelines.
Researchers discovered that certain proteins associated with Alzheimer's disease are stored in dormant cancer cells as amyloid bodies. Disaggregation of these bodies can reactivate the cancer cells. The study identified ribosomal intergenic noncoding RNA as a target for drug discovery to prevent amyloid body disaggregation.
Researchers discovered a nuclear protein, EYA1, that contributes to neuroblastoma's aggression. The protein migrates to the nucleus in more aggressive forms of the disease, and its structure can be altered by inhibiting an enzyme called PRMT1.
A new study identifies a previously unknown 'off-switch' for cancer based on the protein TMX1, which can slow down tumor growth and promote resistance to cell death mechanisms. This breakthrough offers hope for developing new therapeutic approaches and improving chemotherapy efficiency.
Researchers at the University of Bradford have discovered a way to prevent chemotherapy resistance in lung cancer by blocking a protein called Ran-GTP. Suppressing this protein also causes cancer cells resistant to gefitinib to become re-sensitized, offering new hope for treatment.
Researchers have identified a strategy to selectively sensitize certain cancer cells to radiation therapy using antibody drug conjugates (ADCs), which could improve tumor control and reduce treatment-related side effects in HER2-positive tumors. The study shows promise in sensitizing these cancers to radiation and chemotherapy.
A new study by University of Connecticut researchers reveals that larger particles, approximately 2 microns in size, are most effective for delivering cancer drugs to tumor sites. Smaller particles, however, tend to skip through blood cells and reach the target site less frequently.
Researchers identify two gut bacteria that activate cancer-fighting T cell immune responses, enhancing the effects of cyclophosphamide. These microbial-driven immune responses predicted longer progression-free survival in advanced lung and ovarian cancer patients treated with chemo-immunotherapy.
Researchers at Sylvester Comprehensive Cancer Center have identified two leukemia-targeting drugs that could be used to treat breast and ovarian cancers by inhibiting HDACs. The study's genetically engineered cell line, BPLER, exhibited key traits associated with cancer stem cells and showed long-lasting effects of the inhibitors.
A new study found that working memory dysfunctions and depression are predictors of non-adherence to oral cancer therapies. The research highlights the importance of assessing cognitive functions before initiating treatment to identify patient profiles at risk of non-adherence.
Researchers found that inhibiting glucose-regulated protein 78 (GRP78) restores sensitivity to tamoxifen in resistant breast cancer. Silencing GRP78 toxically stresses breast cancer cells, leading to cell death. Adding tamoxifen to a GRP78 inhibitor offers an effective combination, enhancing the treatment's effectiveness.
Researchers at Sylvester Comprehensive Cancer Center have identified a receptor that slows breast cancer metastasis when targeted. By blocking the receptor for advanced glycation end-products (RAGE), scientists decreased tumor growth, reduced angiogenesis and inflammation, resulting in lower metastatic rates to the lung and liver.
A recent study found that nearly a third of Medicare patients with chronic myeloid leukemia did not start treatment within six months due to high out-of-pocket costs. However, patients who had access to subsidies to cover drug costs started treatment 50 days sooner on average.
Researchers at Dana-Farber Cancer Institute have found that CML stem cells die in response to inhibition of the protein Ezh2, suggesting a potential cure for some patients. Adding Ezh2-targeting agents to standard treatment could dramatically shorten the treatment period and achieve a cure.
Researchers at The Wistar Institute discovered that BET inhibitors can suppress PD-L1 activity, a major therapeutic target in various tumors. This approach may reduce side effects while enhancing the immune response against cancer.
An experimental cancer drug called pevonedistat has shown significant promise in stopping melanoma, possibly other cancers. The drug works by blocking a specific protein that allows malignant cells to replicate rapidly.
A recent study published in the British Journal of Sports Medicine found that engaging in regular physical activity may help mitigate the risks associated with excessive alcohol consumption. The research analyzed data from eight British population cohorts and discovered a positive correlation between moderate to high levels of physical...
Researchers discovered a combination of two inhibitor drugs that can stop CML completely and significantly lower treatment costs. The study, published in Science Translational Medicine, found encouraging response and cure rates for both chronic phase and blast crisis, offering new hope for patients.
Researchers identified dopamine receptor DRD2 as a key molecule in pancreatic cancer. Blocking the receptor inhibited cancer growth, while its blockade also slowed tumor growth in mice.
The DOE's Exascale Computing Project awards $39.8 million to 15 research teams, including Argonne-led initiatives focusing on cosmology, precision medicine, and urban systems. These projects will drive advancements in high-performance computing for scientific discovery, national security, and economic competitiveness.
A research team from UC San Diego and Monash University identified 38 lead compounds that exhibit strong affinity and high selectivity for the M2 mAChR binding site. These compounds target allosteric binding sites, which are built around a more diverse genetic sequence and structure than orthosteric binding sites.
Researchers have identified three distinct subtypes of esophageal cancer based on genetic signatures, paving the way for tailored treatments. The study suggests patients with specific weaknesses in their DNA repair pathways or immune systems may benefit from targeted therapies, including PARP inhibitors and immunotherapy drugs.